Advances in the management of patients with non-Hodgkin's lymphoma

Expert Review of Anticancer Therapy

Volumn 1, Issue 1, 2001, Pages 43-52

  Lionberger, Jack M ^a   Armitage, James O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Allogeneic; Antibiotic; Antisense; Autologous; Lymphoma; Monoclonal; Transplantation; Vaccine

Indexed keywords

ALPHA2A INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGONUCLEOTIDE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; TOSITUMOMAB; TUMOR ANTIGEN; VINCRISTINE;

CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HELICOBACTER PYLORI; HUMAN; HUMAN T CELL LEUKEMIA VIRUS; IMMUNOMODULATION; INCIDENCE; MEDICAL DECISION MAKING; MORBIDITY; NONHODGKIN LYMPHOMA; PATIENT CARE; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0035557912     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.1.43     Document Type: Review

References (76)

1. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997
2. Principles of the revised European-American lymphoma classification
3. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
4. Diffuse large B-cell lymphoma outcome prediction by gene expression profiling
5. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
6. Epidemiology of non-Hodgkin's lymphoma: Recent findings regarding an emerging epidemic
7. Cancer statistics, 2001
8. A predictive model for aggressive non-Hodgkin's lymphoma
9. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial
10. Prognostic factors for survival of non-Hodgkin's lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation
11. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
12. CHOP versus MACOP-B in aggressive lymphoma - A Nordic Lymphoma Group randomised trial
13. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: Long-term results
14. Autologous bone marrow versus non-mobilized peripheral blood stem cell transplantation for lymphoid malignancies: A prospective, comparative trial
15. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the jury
16. Consensus conference on high-dose therapy with hematopoietic stem cell transplantation in diffuse large-cell lymphoma: Types of cells, optimal mobilization of stem cells-positive and negative selection
17. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma
18. Allogeneic bone marrow transplantation for lymphoma
19. High-dose chemotherapy and autologous hematopoietic stem cell transplantation: The lymphoma experience and its potential relevance to solid tumors
20. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin
21. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
22. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
23. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
24. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma
25. Ifosfamide, carboplatin and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
26. Ifosfamide, etoposide, epirubicine and G-CSF: An effective mobilization regimen for PBSCT in heavily pretreated patients
27. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: One-half of patients significantly mobilize malignant cells
28. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma
29. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
30. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
31. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation
32. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
33. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience
34. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting
35. The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
36. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a Phase II clinical trial
37. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
38. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin's lymphoma: A retrospective series on 126 patients from a single center
39. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol- a Groupe d'Etude des Lymphomes de l'Adulte study
40. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized Phase III EORTC study
41. Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
42. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
43. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co-operative Study Group
44. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
45. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
46. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation
47. Allogeneic bone marrow transplantation for low-grade lymphoma
48. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma
49. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
50. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies
51. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
52. Multicenter Phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas
53. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma
54. (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
55. Radiolabeled antibody therapy of B-cell lymphomas
56. 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma
57. Monoclonal antibody therapy of cancer
58. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
59. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
60. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
61. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
62. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha- 2a
63. A multicenter, randomized Phase II study of rituximab (chimeric anti-CD20 mAb) at two dosages in patients wit relapsed or refractory intermediate or high-grade NHL (IHG-NHL) or in elderly patients in first-line therapy
64. MABTHERA (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL), Interim results of a randomized GELA trial
65. Anti-idiotype vaccines for human follicular lymphoma
66. DNA vaccination against cancer antigens
67. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
68. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma -long-term results of a clinical trial
69. Gastric MALT lymphoma: From concept to cure
70. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma
71. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma
72. Gastric mucosa-associated lymphoid tissue lymphomas: More than a fascinating model
73. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma
74. Primary cutaneous marginal zone B-cell lymphoma: A recently described entity of low-grade malignant cutaneous B-cell lymphoma
75. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: Complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a
76. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma